Many pharma companies chase advanced AI without solving the foundational challenge of data integration. With only 10% of firms having unified data, true personalization is impossible until a central data platform is established to break down the typical 100+ data silos.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

Marketing leaders pressured to adopt AI are discovering the primary obstacle isn't the technology, but their own internal data infrastructure. Siloed, inconsistently structured data across teams prevents them from effectively leveraging AI for consumer insights and business growth.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

AI models fail in business applications because they lack the specific context of an organization's operations. Siloed data from sales, marketing, and service leads to disconnected and irrelevant AI-driven actions, making agents seem ineffective despite their power. Unified data provides the necessary 'corporate intelligence'.

Before deploying AI across a business, companies must first harmonize data definitions, especially after mergers. When different units call a "raw lead" something different, AI models cannot function reliably. This foundational data work is a critical prerequisite for moving beyond proofs-of-concept to scalable AI solutions.

Historically, MedTech sales success depended on personal relationships built over decades. AcuityMD's founder realized that synthesizing disparate public data provides deep customer insights, allowing new innovators to compete without an established network.

Before complex modeling, the main challenge for AI in biomanufacturing is dealing with unstructured data like batch records, investigation reports, and operator notes. The initial critical task for AI is to read, summarize, and connect these sources to identify patterns and root causes, transforming raw information into actionable intelligence.